Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
about
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.Application of next generation sequencing in the diagnosis and management of mast cell leukemia.Targeted Treatment Options in Mastocytosis.Systemic Mastocytosis with Associated Chronic Lymphocytic Leukemia: A Matter of Diseases or Prognostic Factors?The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing.KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.SOHO State-of-the-Art Update and Next Questions: MPN.The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.Clonal eosinophil and mast cell diseases: different in the same way?
P2860
Q34552564-A519315B-E15C-4FEB-BCFB-6AAF914C48F9Q37706037-B43D215C-DA3C-446B-9EC9-C8520BF5D234Q38642037-4431E925-AFD8-424C-9E88-807BFCD2E021Q38661465-DAC1CC28-8A5E-4D30-9E36-2E8539F91B67Q38698612-3FE55792-AB38-47BE-958E-BDEFF8E80A17Q38904250-C681E38A-6926-4E8D-875F-0A884B26D589Q39267824-1C854E5F-99E3-4D44-A92F-C9A279400E6BQ39601719-A1103FC1-0F23-4734-A089-518F0785F070Q39743763-A8D304A5-CEC9-4DF9-8042-7433EFFBD612Q40063508-0C426FFA-D67B-47C8-B54B-6186B51E54BAQ41061871-0FD58867-E242-45A0-85A7-A3C860A8D14DQ41253739-E3EF3E6D-AB46-4DE3-BBA5-AB833BF0EA0AQ42234623-8A15FD4A-37CB-4DD9-B8DE-C2CBEC274691Q42327796-FDC4C4FD-6916-4EA9-9CF3-EB6D9A66B6D0Q47727992-EB16E4A8-91FC-4B26-9807-B75E439B362EQ47896520-F0AEB059-D47D-4D92-A3B4-8B5BECC7E010Q48277701-5E09A730-8DBE-43CB-84BF-90C2C06F0A56Q49580473-71C87BDF-A197-4250-AB99-480C4ABD86CCQ50035104-AF4F9AD6-EF44-4C08-81A4-4F4955964CE3Q55029786-F1EC5B8D-E65C-4A4F-80FA-960794E78AC5Q57216516-58F09EFC-1EC6-4303-B423-1A4ABF858A2A
P2860
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Additional mutations in SRSF2, ...... dvanced systemic mastocytosis.
@en
type
label
Additional mutations in SRSF2, ...... dvanced systemic mastocytosis.
@en
prefLabel
Additional mutations in SRSF2, ...... dvanced systemic mastocytosis.
@en
P2093
P2860
P356
P1433
P1476
Additional mutations in SRSF2, ...... dvanced systemic mastocytosis.
@en
P2093
A Fabarius
G Metzgeroth
M Meggendorfer
M Pfirrmann
N C P Cross
P2860
P2888
P304
P356
10.1038/LEU.2015.284
P577
2015-10-14T00:00:00Z
P5875
P6179
1045661504